AXSM | Axsome Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	121.02 - 124.67
52 Week Range	64.11 - 139.13
Beta	0.59
Implied Volatility	49.12%
IV Rank	23.01%
Day's Volume	509,631
Average Volume	965,447
Shares Outstanding	48,765,400
Market Cap	5,957,668,918
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-11-19

Valuation
Profitability
Growth
Health
P/E Ratio	-20.40
Forward P/E Ratio	-10.05
EPS	-5.99
1YR Price Target	59.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	607
Country	USA
Website	AXSM

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.

AXSM's peers: ANVS, ATNM, AUPH, AVXL, INCY, IMGN, SRPT, ACAD, VKTX, MDGL, MCRB, ICPT, TGTX, TERN, HEPA, AKRO, RETA, DAWN, BPMC, PDSB, AMLX, BCRX, CPRX, SAVA, SLS, VERU

*Chart delayed

Analyzing fundamentals for AXSM we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AXSM Fundamentals page.

Watching at AXSM technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on AXSM Technicals page.